OPK

OPK

USD

OPKO Health Inc. Common Stock

$1.410+0.040 (2.920%)

Echtzeitkurs

Healthcare
Diagnostics & Research
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.370

Hoch

$1.430

Tief

$1.370

Volumen

2.69M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.1B

Branche

Diagnostics & Research

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.21M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $1.11Aktuell $1.410Hoch $2.04

Ähnliche Nachrichten

Analyst Upgrades

Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

Jefferies analyst Maury Raycroft downgrades OPKO Health from Buy to Hold and lowers the price target from $2 to $1.6.

Mehr anzeigen
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6
Analyst Upgrades

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Barrington Research analyst Michael Petusky maintains OPKO Health with a Outperform and maintains $2.25 price target.

Mehr anzeigen
Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target
GlobeNewswire

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) --

Mehr anzeigen
OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire

OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28,

Mehr anzeigen
OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
GlobeNewswire

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial

Mehr anzeigen
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.